Name: 8th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference
Start: 2024-03-07
End: 2024-03-08
Location: Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
NEW ANTIBODIES DEVELOPMENTS AND UPDATES
Keynote Presentation- HLA-agnostic T-cell recognition of cancer Andrew Sewell , Distinguished Research Professor and Wellcome Trust Senior Investigator,, Cardiff University	09:00 - 09:30
IgE Immunotherapy from Concept to Translation Sophia Karagiannis, Professor, Translational Cancer Immunology and Immunotherapy, Kings College London, UK	09:30 - 10:00
Investigating PD-L1 expression in Circulating Tumor Cells of metastatic cancer patients, using Parsortix® system. Anne-Sophie Pailhes-Jimenez, Senior Director, Head of R&D, ANGLE Europe Limited	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Targeting myeloid cells to augment antibody immunotherapy Ali Roghanian, Associate Professor, Cancer Immunology & Immunotherapy, University of Southampton	11:15 - 11:45
From Biomarker Discovery to Diagnostic: Navigating the Translational Journey Valerie Balme, Associate Director, Business Development, Veracyte Nathalie Steinhoff, Scientist, Cancer Immunotherapy, Numab Therapeutics AG	11:45 - 12:15
Fc Engineering to overcome suppressive tumour microenvironments Stephen Beers, Immunology and Immunotherapy, University of Southampton, Professor	12:15 - 12:45
Preclinical mouse models for I/O research Jianming Xu, Director, InVivo Pharmacology, GemPharmatech	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
NEW ANTOBODY FORMATS & CELL THERAPY
Gamma delta T cells as cancer immunotherapeutics Jonathan Fisher, T-Cell Immunotherapy, Group Leader, University College London	14:15 - 14:45
A novel redirecting antibody targeting SCLC Lindy Durrant, Professor of Cancer Immunotherapy, CEO, ScanCell Ltd	14:45 - 15:15
Boosting Cancer Therapy in immunotherapy with next microbiome generation co-cultured product Nathalie Corvaia, Chief Scientific Officer, MaaT Pharma	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Tumour micro environment and CAR-T Cell Therapy Etienne De Braekeleer, Senior Scientist - Cell Biology & Research Immunology, AstraZeneca	16:30 - 17:00
iPSC derived cell therapies for the treatment of cancer Michael Epstein, VP, Head of Translational Research, Evotec	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30
Drinks Reception & Networking .....End of Day 1.....	17:30 - 17:30

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:50 - 09:00
CAR-T CELL THERAPY DEVELOPMENTS AND UPDATES
Keynote Presentation- CAR T-cell immunotherapy of solid tumours: moving through the generations John Maher, Chief Scientific Officer, Leucid Bio	09:00 - 09:30
A novel Neuropilin-1 (NRP1) antisense oligonucleotide (ASO) with strong in vivo antitumor activity as single agent and in combination with immune checkpoint inhibitors Konstantin Petropoulos, Chief Business Officer, Secarna Pharmaceuticals	09:30 - 10:00
Nu.Q® Discover – Quantitative nucleosome biomarker profiling of the tumour microenvironment Mark Eccleston, Founder and Chief Technology Officer, Volition	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Precise spatial multiplexing with ChipCytometry: An open-source solution to high-throughput spatial biology Steve Hawthorn, Regional Sales Manager EMEA, Canopy Biosciences®	11:15 - 11:45
Programmable and autoregulated viral vectors for new applications of gene therapy Farzin Farzaneh, CSO, ViroCell Biologics Ltd Professor of Molecular Medicine, King’s College London	11:45 - 12:15
Targeted T-cell therapy in solid tumors – bringing the first engineered T-cell therapy from discovery to BLA in sarcoma Joanna Brewer, Chief Scientific Officer, Adaptimmune	12:15 - 12:45
T cell mechanostimulation as a promising approach for enhancing immunotherapies Sebastian Lickert, Group Lead, ETH Zürich	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
NEW CHECKPOINTS FOR IO-PERSONALIZED IMMUNOTHERAPY
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	14:15 - 14:45
Enabling immunotherapy responses in solid tumours through engineered live biotherapeutics Pedro Correa de Sampaio, Co-Founder, CEO,, Neobe Therapeutics	14:45 - 15:15
New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDCline) Eric Halioua,* President & Chief Executive Officer, PDC*line pharma SA	15:15 - 15:45
Afternoon Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Humabody® based novel anti-cancer immunotherapies Phillip Brailey, Senior Scientist, Crescendo Biologics	16:30 - 17:00
Anti-CD270 antibody checkpoint inhibitor for cancer treatment: Swing around patient’s CD270 immunosuppressive disadvantage Louis Boon, CSO and Board Member, JJP Biologics	17:00 - 17:30
Closing Remarks from the Chairperson	17:30 - 17:30
Drinks Reception & Networking .....End of Day 1.....	17:30 - 17:30

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
PRE-CLINICAL AND TRANSLATIONAL IO DEVELOPMENTS-PERSONALIZED CANCER IMMUNOTHERAPY
Keynote Presentation: Cross Training technology: augmenting cross-presentation of neo-antigens Raj Mehta, Chief Executive Officer, Adendra Therapeutics Ltd	09:00 - 09:30
Personalized Immunotherapies: Past, Present and Future Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca	09:30 - 10:00
Unlocking IL-2 therapeutic power using Attenukine™ platform Iris Hecht, Sr. Director, Project Leader, Specialty Projects, Teva Pharmaceuticals	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
LATEST DEVELOPMENTS & TRENDS IN IO RESEARCH
Generative AI designed Personalized Neoantigen Vaccines Daniela Kleine-Kohlbrecher, Senior Project Manager Immune Oncology, Evaxion Biotech	11:15 - 11:45
Exploring γδT Reprogramming as a Solution for Donor Material Access and Donor-to-Donor Variability Daria Paruzina, Senior Manager of Product Development and Platform Expansion, TC BioPharm	11:45 - 12:15
Monocytes and Macrophages in Ovarian Cancer, Biomarker and therapeutic Opportunities in their Overlooked immune Checkpoints Fernando Oneissi Martinez Estrada, Senior Lecturer in Innate Immunology, University of Surrey	12:15 - 12:45
Cancer Vaccines: bringing safety and specificity to immunotherapy John Maudsley, CEO, Cancer Vaccines Ltd	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care John Maher, Chief Scientific Officer, Leucid Bio John Maudsley, CEO, Cancer Vaccines Ltd Elizabeth Sheppard, Global Pricing & Market Access Director, Oncology Diagnostics,, AstraZeneca Louis Boon, CSO and Board Member, JJP Biologics	14:15 - 14:45
Closing Remarks from the Chairperson	14:45 - 14:50
END OF CONFERENCE	14:50 - 14:50